Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Large B-Cell, Diffuse 44Breast Neoplasms 30Lymphoma 29Sarcoma 27Hodgkin Disease 24Triple Negative Breast Neoplasms 20Burkitt Lymphoma 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Neoplasms 15Lymphoma, Follicular 15Ovarian Neoplasms 14Lymphoma, B-Cell 14Lymphoma, Non-Hodgkin 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, T-Cell, Peripheral 9Endometrial Neoplasms 9Neuroblastoma 7Neoplasm Metastasis 7Lymphoma, Mantle-Cell 7Liposarcoma 7Leukemia 7Fallopian Tube Neoplasms 7Recurrence 6Multiple Myeloma 6Leiomyosarcoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Osteosarcoma 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Inflammatory Breast Neoplasms 5

Interventions

Vincristine 1Radiotherapy 1Irinotecan 1Ifosfamide 1Filgrastim 1Etoposide 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant mesenchymal tumor × Doxorubicin × 1 year × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡